Can you provide the average price target for HEALTH CATALYST INC stock?
15 analysts have analysed HCAT and the average price target is 2 USD. This implies a price increase of 50.65% is expected in the next year compared to the current price of 1.33.
NASDAQ:HCAT • US42225T1079
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HEALTH CATALYST INC (HCAT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-18 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2026-03-13 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2026-03-13 | Stephens & Co. | Maintains | Equal-Weight -> Equal-Weight |
| 2026-03-13 | Stifel | Maintains | Hold -> Hold |
| 2026-03-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-13 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-09 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-11 | Stifel | Maintains | Hold -> Hold |
| 2025-11-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-08 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-10-07 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-09-05 | BTIG | Reiterate | Neutral -> Neutral |
| 2025-08-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-28 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-08-27 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-08-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-08-08 | Stifel | Maintains | Hold -> Hold |
| 2025-08-08 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-07-09 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-05-08 | Stifel | Maintains | Hold -> Hold |
| 2025-05-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-25 | Citigroup | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 295.938M 7.15% | 306.584M 3.60% | 311.136M 1.48% | 285.84M -8.13% | 285.41M -0.15% | 299.86M 5.06% | |
| EBITDA YoY % growth | -44.735M 48.46% | -14.023M 68.65% | 14.396M 202.66% | 35.997M 150.05% | 37.562M 4.35% | 49.544M 31.90% | |
| EBIT YoY % growth | -86.958M 35.63% | -55.454M 36.23% | -36.104M 34.89% | -17.827M 50.62% | -10.661M 40.20% | -2.606M 75.55% | |
| Operating Margin | -29.38% | -18.09% | -11.60% | -6.24% | -3.74% | -0.87% | |
| EPS YoY % growth | 0.15 155.56% | 0.28 86.67% | 0.19 -32.14% | 0.14 -26.63% | 0.16 12.19% | 0.23 50.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.02 74.83% | 0.03 -16.21% | 0.03 -49.00% | 0.05 -39.90% | 0.06 269.49% | 0.08 133.32% | 0.07 122.23% | 0.09 83.86% |
| Revenue Q2Q % growth | 70.555M -11.15% | 72.167M -10.60% | 71.714M -6.04% | 71.388M -4.41% | 69.673M -1.25% | 71.803M -0.50% | 72.468M 1.05% | 72.291M 1.26% |
| EBITDA Q2Q % growth | 8.265M 753.88% | 9.041M -32.23% | 8.688M -71.01% | 10.007M -78.84% | 8.675M 4.96% | 9.461M 4.65% | 9.33M 7.39% | 10.816M 8.08% |
| EBIT Q2Q % growth | -7.007M 48.42% | -6.251M 46.41% | -6.725M 12.13% | -4.949M -54.50% | -1.034M 85.25% | 336.6K 105.38% | -825.435K 87.73% | 773.16K 115.62% |
All data in USD
15 analysts have analysed HCAT and the average price target is 2 USD. This implies a price increase of 50.65% is expected in the next year compared to the current price of 1.33.
HEALTH CATALYST INC (HCAT) will report earnings on 2026-05-12.
The consensus EPS estimate for the next earnings of HEALTH CATALYST INC (HCAT) is 0.02 USD and the consensus revenue estimate is 70.56M USD.
The consensus rating for HEALTH CATALYST INC (HCAT) is 73.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.